On July 14, 2014, Mylan Inc. announced that it has entered into a definitive agreement with Abbott whereby Mylan will acquire Abbott’s non‑U.S. developed markets specialty and branded generics business in an all‑stock transaction. Upon closing, Abbott will receive 105 million shares of the combined company worth approximately $5.3 billion based on Mylan’s closing price […]
↧
